
# ASSESSMENT OF TEDIZOLID FOR USE IN GRAM-POSITIVE BACTERIAL INFECTIONS BACKGROUND: REAL WORLD DATA

**E. TEJEDOR TEJADA1, D. RUBIO CALVO2, S. CANO DOMINGUEZ3, A. DORDA BENITO1, R. SACREST GÜELL1**

1HOSPITAL UNIVERSITARIO JOSEP TRUETA, PHARMACY, GIRONA, SPAIN.

2HOSPITAL DE PONIENTE, PHARMACY, ALMERIA, SPAIN.

3HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES, PHARMACY, GRANADA, SPAIN.

## Background and importance

Tedizolid has been licensed for the treatment of acute bacterial skin and soft tissue skin infections in adults**.**




## Aim and Objectives

To evaluate the effectiveness and safety of tedizolid in gram-positive bacterial infections.

## Materials and Methods

•Observational, retrospective, multicenter study. The study period was June 2020-March 2021. The following variables were collected: age, sex, dose, type of infection, previous antibiotic, reason for alternative prescription, duration of treatment.

**Efficacy**

**Security**




.

•The tools used were:

## Results

•Thirty-six patients

• The dose 200 milligrams every 12 hours

• The type of infection collected was: soft tissue (37.5%) and systemic (62.5%).

• **Efficacy:** 100% case clinics.




•**Security** Hematological levels (Before vs after)

platelets (85,000 vs 115,000), hemoglobin (10.4 vs 8.2) and neutrophils (1.8 vs 5.1 10X3/µl).

## Conclusion and relevance

Tedizolid can be considered as an alternative to its homologue, linezolid, both in skin and parts infections and in systemic infections by Gram-positive microorganisms

**26AC-0627**
**4CPS-141**